

ASX Announcement
06 Sep 2023

emyria

A clinical stage biotech informed by patient experience.
Tackling unmet needs in neuroscience and mental health.

Notice to Optionholders of Non-Renounceable Entitlement Offer

We write to you as the registered holder of options (**Options**) to acquire fully paid ordinary shares (**Shares**) in the capital of Emyria Limited (ACN 625 085 734) (ASX: EMD) (**Emyria** or **Company**).

Pursuant to the prospectus lodged with ASIC on 5 September 2023 (**Prospectus**), Emyria is undertaking a non-renounceable entitlement issue of 1 new Share for every 7.5 existing Shares held on the record date, being 5.00pm (AWST) on 13 September 2023 (**Record Date**) at an issue price of $0.075 per new Share to raise approximately $3.1 million (before costs), together with 1 free attaching Option for every 2 new Shares applied for and issued (**Offer**).

Capitalised terms used, but not defined, in this letter have the meaning ascribed to them in the Prospectus.

Your participation

Pursuant to the terms of the Options you currently hold, there is no entitlement to participate in the Offer unless you exercise your Options into Shares and are entered onto the register as a shareholder of the Company by the Record Date.

If you wish to participate in the Offer, a notice of exercise and payment of the Options' exercise price should be lodged with the Company with sufficient time to ensure that you are registered as a shareholder of the Company by the Record Date.

If you do not wish to participate in the Offer, no action is required.

Further details

Details of the Offer are contained in the Prospectus.
The Prospectus can be accessed from the ASX and Company websites, www.asx.com.au and https://investorhub.emyria.com/announcements respectively. It is important that you read the Prospectus carefully before deciding whether to exercise your Options and participate in the Offer.

For all enquiries concerning the Offer, please contact the Company by telephone on +61 (08) 6559 2800 or email at info@emyria.com. For all general shareholder enquiries, please contact the Company's Share Registry, Automic Pty Ltd, on +1300 288 664. You should also consult your stockbroker, solicitor, accountant or other suitably qualified professional adviser to evaluate whether or not to participate in the Offer.

This release has been approved by the Board of Emyria.